TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 and ≤65 years of age at the time of consent.~* Patients with Atopic Dermatitis~* Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit~* Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit~* static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit~Exclusion Criteria:~* Serological evidence of hepatitis B virus or hepatitis C virus infection~* Known human immunodeficiency virus infection~* Ongoing treatment with specific or non-specific hyposensitization therapy for AD~* Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week prior to randomization~* History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization.~* Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferon-gamma release assay.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group1 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group2 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group3 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group4 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group5 (Type: EXPERIMENTAL): Part A: Placebo Part B: nemolizumab (CIM331)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phycosocial Impact of Bleaching Teeth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy patients with Anterior teeth without restorations, previous bleaching procedures, cervical lesions, or dental pain~Exclusion Criteria:~* Pregnant or lactating,~* Had moderate or severe fluorosis,~* Tetracycline stains,~* Orthodontic treatment,~* Periodontal disease,~* Orofacial tumors,~* Trauma,~* Tooth malformation Were taking analgesic, anti-inflammatory, or antibiotic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- bleaching teeth (Type: EXPERIMENTAL): Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female in good health~* Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last study vaccine.~Exclusion Criteria~* History of invasive pneumococcal disease~* Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.~* Known or suspected impairment of immune function~* Coagulation disorder contraindicating intramuscular vaccination~* History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Female participant: positive urine or serum pregnancy test~* Prior administration of any pneumococcal vaccine~* Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.~* Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue \[e.g., bursa, tendon steroid injections\], and inhaled/nebulized steroids are permitted).~* Received immunosuppressive therapy~* Received a blood transfusion or blood products within 6 months of enrollment~* Participated in another clinical study of an investigational product within 2 months of enrollment~* Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Known hormone refractory disease~* Multiple skeletal metastases (≥ 2 hot spots) on bone scintigraphy~* No intention to use cytotoxic chemotherapy within the next 6 months~* Either regular (not occasional) analgesic medication use for cancer related bone pain or treatment with EBRT (External Beam Radiation Therapy) for bone pain~Exclusion Criteria:~* Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period~* Eligible for first course of docetaxel, i.e. patients who are fit enough, willing and where docetaxel is available~* Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period, or failure to recover from adverse events due to cytotoxic chemotherapy administered more than 4 weeks ago~* Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within previous 24 weeks~* Other malignancy treated within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)~* History of visceral metastasis, or visceral metastases as assessed by abdominal/pelvic CT or chest x-ray within previous 8 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) (Type: EXPERIMENTAL): Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients at least 20 years of age~* Patients with diagnosed primary cancer~* Patients with metastatic lesions by CT/MRI~Exclusion Criteria:~* Patients who have contraindication to the MRI examinations~* Patients who have severe renal disorder~* Patients in extremely serious general condition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol 0.1 mmol/kg bw (Type: EXPERIMENTAL): Participants received first injection (intravenous \[i.v.\]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
- Gadobutrol 0.2 mmol/kg bw (Type: EXPERIMENTAL): Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
- Gadoteridol (ProHance) (Type: EXPERIMENTAL): Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic breast adenocarcinoma~* No HER2 overexpression or gene amplification~* Absent or low ER or PR expression~* No previous therapy for metastatic breast cancer is allowed~* Age 18-75 years~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases)~* adequate renal function (serum creatinine \<1.5 times the upper normal limit)~* bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)~* No radiation of measurable disease (except brain metastases)~* No progressive brain metastases according to clinical or radiological criteria~* No brain metastases without prior radiation therapy~* Written informed consent~Exclusion Criteria:~* Active infection~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* History of stroke~* Anticoagulation therapy (except of low dose aspirin \<325mg)~* Other invasive malignancy except nonmelanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Paclitaxel/Carboplatin/Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Patients aged 18 and over with acute headache who met the diagnostic criteria of the International Headache Association (9) for the diagnosis of migraine~Exclusion Criteria:~* Patients who refused to participate in the study~* Patients that took any analgesic medication within six hours before presentation to ED Patients with any additional organic pathology (e.g., hypertension, hypoglycemia, chronic kidney failure, and intracranial masses) pregnant women hemodynamically unstable patients patients with an allergy to the drugs used in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- metoclopramide+ dexketoprofen trometamol (Type: ACTIVE_COMPARATOR): 10 mg metoclopramide+ 50 mg dexketoprofen trometamol
- metoclopramide (Type: EXPERIMENTAL): 10 mg metoclopramide
- dexketoprofen trometamol (Type: EXPERIMENTAL): 50 mg dexketoprofen trometamol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Glaucoma or ocular hypertension in both eyes~* Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering~* Best-corrected visual acuity of 20/100 or better in each eye~* Visual field within 6 months of study entry~Exclusion Criteria:~* Secondary glaucoma~* Active intraocular inflammation or macular edema~* Intraocular surgery or laser surgery within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of Apixaban Crushed Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Healthy participants as determined by no clinically significant deviation from normal in findings of medical history, physical examination, electrocardiograms, vital signs, and clinical laboratory tests.~* Women of childbearing potential allowed. Must be following highly effective methods of contraception~Exclusion Criteria:~* Any significant acute or chronic medical illness~* History of significant head injury within the last 2 years, including individuals with base of skull fractures~* Any major surgery within 4 weeks of study drug administration or anticipated within 2 weeks after completion of the study~* Any gastrointestinal (GI) surgery or GI disease that could impact absorption of study drug~* History of Gilbert's Syndrome~* Inability to tolerate oral medication~* Inability to be venipunctured and/or tolerate venous access~* Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study drug administration~* Any laboratory test results outside of the range of normal, confirmed by repeat results of:~  * Platelet count \<150,000 cells/µL~ * Activated partial thromboplastin time \>upper limit of normal (ULN)~ * International normalized ratio \>ULN~ * Alanine aminotransferase \>ULN~ * Aspartate aminotransferase \>ULN~ * Total bilirubin \>ULN~ * Serum creatinine ≥1.5 mg/dL~ * Hemoglobin \<lower limit of normal (LLN)~ * Hematocrit \<LLN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Apixaban, 10 mg (whole tablets) (Type: EXPERIMENTAL): Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
- Apixaban, 10 mg (crushed and suspended in water) (Type: EXPERIMENTAL): Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
- Apixaban, 10 mg (crushed and mixed with applesauce) (Type: EXPERIMENTAL): Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Care for Patients With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Eligible nursing home facilities will~* lack any existing dementia program targeting reduction of off-label psychotropic medication use~* each serve \>60 long-term care residents with Alzheimer's or dementia~* meet Center for Medicare \& Medicaid Services' minimum requirements for NHs (e.g., meeting the mandated number of hours of staff training on dementia care, performing regularly scheduled resident assessments).~Exclusion Criteria:~Facilities will be excluded if they have~* less than 60 long-stay residents~* an existing formal dementia care program in place~* an off-label psychotropic medication reduction program~* is located in a state that requires more than the Center for Medicare \& Medicaid Services' minimum for staff training requirements on the topic of dementia care

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- transdisciplinary approach (Type: ACTIVE_COMPARATOR): The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
- multidisciplinary approach (Type: ACTIVE_COMPARATOR): The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients experiencing their first psychotic episode~* Male or Female~* Aged 15-25~Exclusion Criteria:~* Previous treatment with antipsychotic medication (longer than 1 week)~* History of a clinically significant physical illness~* Organic disorder presenting with psychotic symptoms

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, age 18 - 69 years~* Ability to read and understand English~* Subjectively in good health~* Able to stand without assistance for \~10 minutes~Exclusion Criteria:~* Any volunteer with relocation, deployment, or release from active duty in the next 4 months~* Pregnant, or currently breastfeeding, females~* Anyone with chronic health problems (e.g. kidney disease, liver disease, intestinal malabsorption)~* Any volunteer currently taking vitamin D supplementation~* Taking medications for an endocrine disorder, such as Synthroid or oral hypoglycemic agents~* Sarcoidosis~* Medications having a high potential for interaction with vitamin D:~anti-seizure medications, cyclosporine, indinavir (Crixivan) • Adults diagnosed with light allergies: Actinic prurigo, Polymorphous light eruption, Solar urticaria~• Adults diagnosed with light sensitivities: Protoporphyria, Photodermatitis, Xeroderma pigmentosum, Lupus erythematosus, Actinic dermatitis, UV-sensitive syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Standing Phototherapy Kiosk (SPK) (Type: EXPERIMENTAL): Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
- Oral Supplement (Type: ACTIVE_COMPARATOR): Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete